pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Pulmonology · news · pharmadog
← back to Pulmonology
News · Pulmonology
515
stories
Jun 4, 26
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
stat
Jun 4, 26
Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
stat
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 3, 26
Opinion: The medical-billing AI arms race between providers and insurance
stat
Jun 2, 26
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
stat
Jun 1, 26
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
stat
Jun 1, 26
STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
stat
Jun 1, 26
As FDA misses deadline on electric shock ban, disability advocates speak out
stat
Jun 1, 26
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
stat
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
Jun 1, 26
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
stat
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 31, 26
#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
endpoints
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
stat
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
May 29, 26
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
stat
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 29, 26
Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
stat
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 19, 26
Acceleron leaders and Westlake jumpstart new IPF biotech
endpoints
May 19, 26
Full-Life Technologies raises $150M; Quince's reboot with pulmonary drug
endpoints
May 19, 26
Opinion: Britain embraces a Massachusetts experiment on tobacco regulation — just as the state might roll it back
stat
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 18, 26
Opinion: ‘Patient autonomy’ has nothing to do with childhood vaccine policies
stat
← prev
page 14 of 18
next →
